Physician profile
Peter B Weber
NPI 1639165483
$15,235.93
in general payments reported to CMS, 2019-2025
29 companies · $31.65 in 2025
The $31.65 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $7,421 · 2021: $628 · 2022: $447 · 2023: $3,826 · 2024: $194 · 2025: $31.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,529 · Food and Beverage: $450 · Royalty Or License: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,529.45 |
| Food and Beverage | $449.91 |
| Royalty Or License | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $4,435.01 | 2019-2022 | |
| Globus Medical, INC. | $3,615.38 | 2023 | Excelsiusgps Robotic Navigation System |
| Spine Wave, INC. | $3,004.00 | 2019-2024 | Paramount Anterior Cervical Spine System |
| Zimmer Biomet Holdings, INC. | $2,170.24 | 2019-2020 | |
| Ucb, INC. | $305.13 | 2019-2025 | Nayzilam, Fintepla |
| Sk Life Science, INC. | $287.95 | 2021-2024 | Xcopri |
| Depuy Synthes Sales INC. | $207.50 | 2019 | |
| Greenwich Biosciences, INC. | $160.26 | 2019-2021 | |
| Eisai INC. | $150.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $137.96 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $135.78 | 2022 | |
| Medtronic USA, INC. | $121.69 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.72 | 2019 | |
| Livanova USA, INC. | $59.59 | 2019 | |
| Medtronic, INC. | $54.95 | 2022-2023 | Percept Pc Brainsense |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Centinel Spine, LLC | $53.20 | 2020 | |
| Amgen INC. | $46.82 | 2019-2021 | |
| Monteris Medical Corporation | $35.22 | 2019 | |
| Neurocrine Biosciences, INC. | $27.91 | 2019 | |
| Adamas Pharmaceuticals, INC. | $24.92 | 2019 | |
| Aquestive Therapeutics, INC. | $21.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.23 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.69 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.62 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.65 | 2019 | |
| Bausch Health US, LLC | $16.86 | 2019 | |
| Kyowa Kirin, INC. | $15.12 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$853,519.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.